Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference


Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. P.T. in San Francisco.

A live webcast of the presentation will be accessible under the Investor Relations section of the Aimmune website at www.aimmune.com. A replay will be available following the webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies. The Company's Characterized Oral Desensitization ImmunoTherapy (CODITtm) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first, investigational, complex biologic product candidate, PALFORZIAtm (AR101), is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut. The BLA for PALFORZIA is under review by the FDA, which granted PALFORZIA Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The European Medicines Agency (EMA) is reviewing Aimmune's Marketing Authorization Application (MAA) for PALFORZIA, which Aimmune submitted in June 2019. Aimmune initiated a randomized phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019. For more information, please see www.aimmune.com.


These press releases may also interest you

at 07:10
D-Wave Quantum Inc., ("D-Wave" or the "Company") a leader in commercial quantum computing systems, software, and services, today announced financial results for its fourth fiscal quarter and year ended December 31, 2023. "Our momentum is...

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Zilliant, the leader in pricing lifecycle management, today announced it recently concluded a year of rapid growth, delivering two consecutive quarters of 60%+ growth in year-over-year bookings. The company is positioned for continued record growth...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:07
MESCIUS inc., a global provider of award-winning enterprise software development tools, is pleased to announce the release of ActiveReports. NET v18. This major release includes exciting new features and improvements to the ActiveReports ecosystem....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...



News published on and distributed by: